Cargando…

Upregulation of Circulating PD-L1/PD-1 Is Associated with Poor Post-Cryoablation Prognosis in Patients with HBV-Related Hepatocellular Carcinoma

BACKGROUND: The programmed cell death-1 receptor/programmed cell death-1 ligand (PD-1/PD-L1) pathway plays a crucial role in tumor evasion from host immunity. This study was designed to evaluate the association between circulating PD-L1/PD-1 and prognosis after cryoablation in patients with HBV-rela...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zeng, Zhen, Shi, Feng, Zhou, Lin, Zhang, Min-Na, Chen, Yan, Chang, Xiu-Juan, Lu, Yin-Ying, Bai, Wen-Lin, Qu, Jian-Hui, Wang, Chun-Ping, Wang, Hong, Lou, Min, Wang, Fu-Sheng, Lv, Ji-Yun, Yang, Yong-Ping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3164659/ https://www.ncbi.nlm.nih.gov/pubmed/21912640 http://dx.doi.org/10.1371/journal.pone.0023621

Ejemplares similares

High intratumoral metastasis-associated in colon cancer-1 expression predicts poor outcomes of cryoablation therapy for advanced hepatocellular carcinoma
por: Yang, Yong-Ping, et al.
Publicado: (2013)

Association of PD-L1 and HIF-1α Coexpression with Poor Prognosis in Hepatocellular Carcinoma
por: Dai, Xiaomeng, et al.
Publicado: (2018)

Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer
por: Qing, Yi, et al.
Publicado: (2015)

Coexpression of CMTM6 and PD-L1 as a predictor of poor prognosis in macrotrabecular-massive hepatocellular carcinoma
por: Liu, Li-Li, et al.
Publicado: (2020)

Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma
por: Jung, Hae Il, et al.
Publicado: (2017)

Upregulated CANT1 is correlated with poor prognosis in hepatocellular carcinoma
por: Liu, Ting, et al.
Publicado: (2023)

Is PD-1 blockade a potential therapy for HBV?
por: Féray, Cyrille, et al.
Publicado: (2019)

Upregulated PD-1 Expression Is Associated with the Development of Systemic Lupus Erythematosus, but Not the PD-1.1 Allele of the PDCD1 Gene
por: Jiao, Qingqing, et al.
Publicado: (2014)

LncTUG1 promotes hepatocellular carcinoma immune evasion via upregulating PD-L1 expression
por: Wu, Rongshou, et al.
Publicado: (2023)

PD-L1 upregulation by IFN-α/γ-mediated Stat1 suppresses anti-HBV T cell response
por: Liu, LanLan, et al.
Publicado: (2020)

Anti-PD-L1 antibody enhances curative effect of cryoablation via antibody-dependent cell-mediated cytotoxicity mediating PD-L1(high)CD11b(+) cells elimination in hepatocellular carcinoma
por: Tan, Jizhou, et al.
Publicado: (2023)

Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells
por: Dong, Ling, et al.
Publicado: (2016)

Increased both PD–L1 and PD–L2 expressions on monocytes of patients with hepatocellular carcinoma was associated with a poor prognosis
por: Yasuoka, Hidetaka, et al.
Publicado: (2020)

Co-expression of AFAP1-AS1 and PD-1 predicts poor prognosis in nasopharyngeal carcinoma
por: Tang, Yanyan, et al.
Publicado: (2017)

Upregulation of PD-1 expression on circulating CD8+ but not CD4+ T cells is associated with tuberculosis infection in health care workers
por: Shi, Cui-lin, et al.
Publicado: (2021)

Clinical outcomes and influencing factors of PD-1/PD-L1 in hepatocellular carcinoma
por: Wang, Jiting, et al.
Publicado: (2021)

Tumor Infiltrating PD1-Positive Lymphocytes and the Expression of PD-L1 Predict Poor Prognosis of Soft Tissue Sarcomas
por: Kim, Jung Ryul, et al.
Publicado: (2013)

IFN-γ surmounts PD-L1/PD1 inhibition to CAR-T cell therapy by upregulating ICAM-1 on tumor cells
por: Dong, E, et al.
Publicado: (2021)

PD-1 and PD-L1 co-expression predicts favorable prognosis in gastric cancer
por: Wu, Yanhua, et al.
Publicado: (2017)

PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load
por: Zhou, Yajuan, et al.
Publicado: (2017)

HDAC10 Is Positively Associated With PD-L1 Expression and Poor Prognosis in Patients With NSCLC
por: Liu, Xiaomei, et al.
Publicado: (2020)

Chromosome 11q13 amplification correlates with poor response and prognosis to PD-1 blockade in unresectable hepatocellular carcinoma
por: Yan, Kai, et al.
Publicado: (2023)

Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy
por: Yue, Chunyan, et al.
Publicado: (2018)

Investigation of the efficacy and safety of cryoablation and intra-arterial PD-1 inhibitor in patients with advanced disease not responding to checkpoint inhibitors: An exploratory study
por: Wei, Fuqun, et al.
Publicado: (2022)

Upregulated TUBG1 expression is correlated with poor prognosis in hepatocellular carcinoma
por: Zhang, Kainan, et al.
Publicado: (2022)

Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade
por: Zhang, Min, et al.
Publicado: (2019)

Evaluation of circulating PD-1 and PD-L1 as diagnostic biomarkers in dogs with tumors
por: Song, Doo-Won, et al.
Publicado: (2021)

Progress of PD-1/PD-L1 signaling in immune response to liver transplantation for hepatocellular carcinoma
por: Ju, Feng, et al.
Publicado: (2023)

Prognostic Nutritional Index Predicts Outcome of PD-L1 Negative and MSS Advanced Cancer Treated with PD-1 Inhibitors
por: Zhang, Yan, et al.
Publicado: (2022)

Outcomes of ultrasound-guided percutaneous argon-helium cryoablation of hepatocellular carcinoma
por: Yang, Yongping, et al.
Publicado: (2011)

Novel phthalimides regulating PD-1/PD-L1 interaction as potential immunotherapy agents
por: Sun, Chengliang, et al.
Publicado: (2022)

PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma
por: Bi, Xi-wen, et al.
Publicado: (2016)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

Radiomics models based on multisequence MRI for predicting PD-1/PD-L1 expression in hepatocellular carcinoma
por: Gong, Xue-Qin, et al.
Publicado: (2023)

Higher serum sPD-L1 levels after radiotherapy indicate poor outcome in hepatocellular carcinoma patients
por: Zhang, Yang, et al.
Publicado: (2022)

PD-1/PD-L1 axis in organ fibrosis
por: Zhao, Youliang, et al.
Publicado: (2023)

Anti-PD-1 Immunotherapy Improves the Efficacy of Hepatic Artery Infusion Chemotherapy in Advanced Hepatocellular Carcinoma
por: Mei, Jie, et al.
Publicado: (2021)

PD-L1 is Fascinating but IDO Needs Attention in Non-HCV and Non-HBV-Associated Hepatocellular Carcinoma Patients
por: Asghar, Kashif, et al.
Publicado: (2023)

PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
por: Zhang, Ke, et al.
Publicado: (2022)

Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models
por: Kurino, Taiki, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ah9aiss2306ddv8ppkkn52v2b6